Jump to a section
Start here (30 seconds)
Gene therapy is a way of treating disease by changing how a cell uses genetic instructions — often by delivering a working copy of a gene, fixing a faulty one, or adjusting how a gene is read.
It has helped some children with rare conditions in ways that were not possible before. It is also new, complex, expensive, and not right for every child or every disease.
Your job is not to become a scientist overnight. Your job is to ask clear questions, understand the tradeoffs, and never feel rushed into a decision at 2am.
What gene therapy is
Most of our cells carry DNA — a set of instructions that tell the body how to work. When one of those instructions is missing, broken, or wrong, it can cause a genetic disease.
Gene therapy tries to address the problem at the source — the genetic instructions — rather than only treating symptoms.
There are three main approaches you may hear about:
- Gene addition (replacement) — A working copy of a gene is delivered into the body, often using a harmless virus as a carrier ("vector"). The new gene helps cells produce what they were missing. Example families may hear about: treatments for spinal muscular atrophy or certain inherited retinal diseases.
- Gene editing — Scientists change the DNA itself — correcting, removing, or disabling a specific piece. Example: CRISPR-based therapies for sickle cell disease.
- Gene regulation — The therapy turns a gene up, down, or off without replacing it entirely.
Treatments may be given inside the body (in vivo — often one infusion or injection) or outside the body (ex vivo — cells are collected, modified in a lab, then returned to the patient).
What gene therapy is not
These misunderstandings come up a lot. It helps to name them plainly.
- It is not a guaranteed cure. Some children improve significantly. Others see smaller changes. Some conditions cannot yet be treated this way at all.
- It is not available for most rare diseases yet. Only a small number of gene therapies are approved. Many more are in research.
- It is not like taking a daily pill. Many are one-time or infrequent treatments with intensive monitoring afterward.
- It is not risk-free. Serious side effects are possible. Your team should explain them honestly.
- It is not the only path forward. Standard medicines, enzyme replacement, clinical trials of other types, and supportive care may still be the right choice — or the only choice available today.
- It does not replace your judgment as a parent. You are allowed to take time, get a second opinion, and say "not yet."
How it works (the simple version)
Every therapy is different, but many follow a pattern like this:
- Testing confirms the diagnosis — Genetic testing identifies the specific change. Gene therapy usually targets a precise mutation or gene, not a vague symptom.
- Your team checks eligibility — Age, disease stage, organ function, antibodies to the delivery vector, and other factors may matter.
- Preparation — This may include immune-suppressing medicines, hospital admission planning, or travel to a specialized center.
- Treatment day — Often a single infusion or procedure at a specialized hospital.
- Close monitoring — Weeks to months of follow-up visits, blood tests, and watching for side effects.
- Long-term follow-up — Many programs track patients for years — sometimes 15 years or more — to understand lasting effects.
A note for exhausted parents: You do not need to memorize this list. Save it. Bring it to the appointment. Ask which steps apply to your child and which do not.
Who might qualify
Eligibility is always specific to the therapy and the disease. In general, doctors look at:
- The exact genetic diagnosis — not just the disease name, but the specific gene and mutation
- Age and disease stage — some therapies work best before certain damage has occurred
- Overall health — liver, immune system, and other organs may affect safety
- Prior treatments — including whether your child already has antibodies that could block the therapy
- Where you live — approved therapies and trials are not available in every country or hospital
If your child does not qualify today, that does not mean forever. New trials open. New therapies are approved. Keep asking — and keep your records organized.
USA vs EU — where things differ
The science is largely the same. How a therapy gets approved, who pays for it, and how your family accesses it can be very different depending on whether you are in the United States or the European Union.
Below, we separate what differs. Shared concepts appear once; region-specific details are in their own boxes.
Who approves gene therapies
How families access treatment
Paying for gene therapy
Pediatric and rare disease support
Both regions offer incentives for developing treatments for children and rare diseases — but the programs have different names and timelines.
Same therapy, different timeline: A gene therapy may be approved in the US but still under EMA review — or approved in the EU but not yet reimbursed in your country. Approval date and access date are not the same thing. Ask your team: "Where is this therapy approved today, and where can we actually receive it?"
7 questions to ask your doctor
Print this section or screenshot it before your appointment. You deserve answers in plain language.
-
Question 1
Is gene therapy actually an option for my child's condition — and their specific gene change?
Gene therapy is not one-size-fits-all. It depends on the exact diagnosis, which gene is affected, and whether a therapy exists or is being studied for that condition.
Ask: "Has gene therapy been approved or studied for this diagnosis and mutation? If not, is anything in development?"
-
Question 2
What type of gene therapy would this be?
There are different approaches — adding a working gene, fixing a faulty one, or turning a gene on or off. The risks, logistics, and who can receive it all change depending on the type.
Ask: "Would this be gene addition, gene editing, or something else — and has it been tested in children like mine?"
-
Question 3
What benefits are realistic — and what do we still not know?
Some children see major improvements. Others see smaller changes. Long-term results are still being followed for many therapies because they are new.
Ask: "What did the studies show — and what is still unknown, especially years later?"
-
Question 4
What are the risks and side effects — including long-term ones?
Gene therapy can have serious risks. Your team should explain them in plain language, not just hand you a consent form.
Ask: "What are the most common side effects, the serious ones, and how would we know if something is going wrong?"
-
Question 5
Is this a one-time treatment, or will my child need repeat doses?
Some gene therapies are designed to last a lifetime after one dose. Others may need to be given again. This affects planning, cost, and follow-up care.
Ask: "Is this one treatment, or will we need to repeat it? What does follow-up look like?"
-
Question 6
How would we access it — approved treatment, expanded access, or clinical trial?
Not every approved therapy is available everywhere. Some families join trials. Some use special access programs while waiting for approval.
Ask: "What is the path for our family — approved use, trial, or compassionate access — and what are the next steps?"
-
Question 7
What will this cost our family, and what help exists?
Gene therapies can be among the most expensive treatments in medicine. Costs and who pays vary sharply between the US and Europe — and even between EU countries.
Ask: "What will insurance or our health system cover? Are there patient support programs, travel funds, or financial counselors we should talk to?"
Words you might hear
- Vector
- A carrier — often a modified virus — used to deliver genetic material into cells.
- In vivo / Ex vivo
- In vivo = treated inside the body. Ex vivo = cells are removed, modified in a lab, then returned.
- ATMP (EU term)
- Advanced Therapy Medicinal Product — the EU category that includes gene therapies, cell therapies, and tissue engineering.
- BLA (US term)
- Biologics License Application — the FDA application for approving a gene or cell therapy.
- Expanded access / Compassionate use
- A pathway to access an investigational therapy outside a clinical trial when no satisfactory alternatives exist.
- Reimbursement (EU)
- The process by which a country decides to fund a medicine through its public health system — separate from EMA approval.
- Long-term follow-up
- Ongoing monitoring required for many gene therapy patients to track safety and durability over years.
What to do next
You do not have to figure this out alone tonight.
- Save or print the 7 questions above for your next appointment.
- Ask your specialist whether a genetic counselor can walk through your child's results with you.
- If you are in the US, search ClinicalTrials.gov for your child's condition.
- If you are in the EU, search the EU Clinical Trials Register and ask about ERN referral.
- Reach out to a disease-specific patient organization — families who have walked this road often know the practical details no brochure covers.
You are not failing by not understanding everything at once.
Gene therapy is genuinely complicated — even doctors specialize in it. Your job is to love your child, ask honest questions, and take it one conversation at a time.